PFS

What is PFS?

PFS, or Post-Finasteride Syndrome, is a complex iatrogenic (drug-induced) condition that spans sexual, physical, and mental side effects that persist in patients for at least three months after stopping the drug— a drug used for hair loss or enlarged prostate. In the early 2000s— only a few years after Finasteride became widely available worldwide— complaints about persistent, debilitating symptoms had begun to sprout on internet forums. Nevertheless, it wasn’t until 2011 that Dr. Michael S. Irwig and S. Kolukula published the first formal paper focusing on the syndrome which soon invoked a regulatory warning by the USA’s Food & Drug Association.

The syndrome is objectively rare, but that doesn’t mean it is menial or unreal. There is no medical consensus as to the exact frequency of PFS. However, some experts, such as the medical editors at Perfect Hair Health believe that the frequency is one in five– to ten–thousand users.

While the symptoms of PFS are relatively well-defined, and an official diagnostic criteria has been outlined by Dr. David Healy in 2022, the pathology of the condition is poorly understood at best. PFS is also used as an umbrella term for enduring dysfunctions induced by 5-alpha reductase inhibitors— drugs that aim to block the enzyme that convert testosterone into dihydrotestosterone (DHT).

Dr. Will Powers, a physician focusing on gender affirmation treatment and post-drug syndromes, believes PFS (and possibly PSSD) is an inability of the cells to excrete hormonal metabolites due to underlying genetic weaknesses further exacerbated by iatrogenic disturbances. It occurs when genetic weaknesses in the enzymes that break down and export hormonal metabolites combine with a drug that further disrupts those same pathways, causing metabolites to pile up inside cells and drown out normal hormonal signaling. He proposed that a UGT2B17 deletion is integral to the acquired inability to excrete metabolites at a cytological level, leading to windows of improvement and crashes as the gradient of metabolite build-up shifts. In 2026, Dr. Powers proposed his theory to the official PFS Congress, you can read more about his experience here.

Dr. Melcalgi, another renowned physician experienced in post-exposure syndromes, has hypothesized that PFS is a consequence of disrupted neurosteroidigenesis. In simple terms, finasteride's blockade of the 5α-reductase enzyme permanently alters the brain's ability to produce the neuroactive steroids it relies on to regulate mood, arousal, stress response, and neuroprotection. In essence, the brain is stuck in a post-drug dysfunction which is not mendable through a washout. Overall, Melcalgi believes that epigenetic changes in the progesterone and testosterone pathways induced by Finasteride does not subside after discontinuation.

Nevertheless, we at PEF are confident that all of these theories hold a certain level of truth. We believe that PFS, like all other post-exposure syndromes, falls under the umbrella of an Infection-Associated Chronic Conditions and Illnesses (IACCI), as outlined by the world-renowned Mount Sinai Hospital.

Unlike its sister condition, PSSD, PFS is more adequately named for its outstanding psychiatric, neurological, sexual, and physical symptoms. While the underlying pathology and neurobiological components are still under investigation, there have been promising reports of improvement— you can read about them here. If you or a loved one are looking for a physician experienced in treating PFS— you can search for them here.